Sugi Predict

Sugi Predict / Compounds / SCHEMBL917692

SCHEMBL917692

SCHEMBL917692

O=S(=O)(O)CCCNCCCCCCO

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ APP P05067 1/20 0.41
▸ CA2 P00918 5/20 0.38
▸ EPHX2 P34913 1/20 0.35
▸ CA1 P00915 3/20 0.34
▸ CA12 O43570 1/20 0.34
▸ CA9 Q16790 1/20 0.34
▸ PAOX Q6QHF9 2/20 0.33
▸ PTGS1 P23219 1/20 0.33
▸ PDE4A P27815 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ SLC6A6 P31641 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ BLM P54132 1/20 0.33
▸ RELA Q04206 4/20 0.33
▸ S1PR2 O95136 2/20 0.31
▸ S1PR4 O95977 2/20 0.31
▸ S1PR1 P21453 2/20 0.31
▸ S1PR3 Q99500 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28285093 1.00 APP (0.41) APPCA2EPHX2CA1CA12
SCHEMBL918521 1.00 APP (0.41) APPCA2EPHX2CA1CA12
SCHEMBL917868 0.98 APP (0.42) APPCA2EPHX2CA1CA12
SCHEMBL918086 0.93 APP (0.42) APPCA2EPHX2CA12CA9
SCHEMBL918374 0.88 APP (0.42) APPCA2EPHX2CA12CA9
SCHEMBL918312 0.88 APP (0.50) APPCA2EPHX2CA1CA12
SCHEMBL11241170 0.86 APP (0.41) APPEPHX2PAOXPTGS1PDE4A
SCHEMBL2121438 0.85 APP (0.48) APPCA2EPHX2CA1CA12
SCHEMBL14742093 0.84 APP (0.37) APPCA2CA12CA9PAOX
SCHEMBL3181168 0.84 APP (0.42) APPEPHX2PTGS1PDE4ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110281951-A1 Compositions and methods for treating amyloidosis BHI LIMITED PARTNERSHIP (CA) 2011-11-17 — — US claimed
JP-4726304-B2 — — 2011-07-20 — — JP claimed
EP-1276483-B1 COMPOSITIONS AND METHODS FOR TREATING AMYLOIDOSIS USING SULPHONATE DERIVATIVES BELLUS HEALTH INT LTD (CH) 2009-09-02 — — EP claimed
US-20090099100-A1 Compositions and methods for treating amyloidosis BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2009-04-16 — — US claimed
EP-1609467-A1 Compositions for treating diseases associated with glycosaminoglycan-associated molecular interactions Neurochem (International) Limited (CH) 2005-12-28 — — EP claimed
US-20050048000-A1 Amyloid targeting imaging agents and uses thereof NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2005-03-03 — — US claimed
JP-2003517458-A — — 2003-05-27 — — JP claimed
EP-1303311-A2 AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF Neurochem, Inc. (CA) 2003-04-23 — — EP claimed
EP-1276483-A2 COMPOSITIONS AND METHODS FOR TREATING AMYLOIDOSIS USING SULPHONATE DERIVATIVES QUEEN'S UNIVERSITY AT KINGSTON (CA) 2003-01-22 — — EP claimed
US-20020193395-A1 Methods and compositions to treat glycosaminoglycan-associated molecular interactions QUEEN'S UNIVERSITY 2002-12-19 — — US claimed
US-20020115717-A1 Amyloid targeting imaging agents and uses thereof NEUROCHEM (INTERNATIONAL) LIMITED (GI) 2002-08-22 — — US claimed
WO-2002007781-A2 AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF NEUROCHEM INC. (CA) 2002-01-31 — — WO claimed
EP-1100487-A2 COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTIONS Neurochem, Inc. (CA) 2001-05-23 — — EP claimed
WO-2000064420-A2 COMPOSITIONS AND METHODS FOR TREATING AMYLOIDOSIS USING SULPHONATE DERIVATIVES QUEEN'S UNIVERSITY AT KINGSTON (CA) 2000-11-02 — — WO claimed
WO-2000006133-A2 COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTIONS NEUROCHEM, INC. (CA) 2000-02-10 — — WO claimed
US-20140329746-A1 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2014-11-06 — — US disclosed
US-8835654-B2 Method and compositions for treating amyloid-related diseases BHI LIMITED PARTNERSHIP (CA) 2014-09-16 — — US disclosed
EP-1100487-A2 COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTIONS Neurochem, Inc. (CA) 2001-05-23 — — EP disclosed
WO-2000006133-A2 COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTIONS NEUROCHEM, INC. (CA) 2000-02-10 — — WO disclosed
US-4029638-A YARNS, SULFONAMIDE GROUPS AKZONA (US) 1977-06-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099100-A1 Compositions and methods for treating amyloidosis TTR, SNCA, ARSA APP 5/4885CA2 888/4885EPHX2 3145/4885
US-20110281951-A1 Compositions and methods for treating amyloidosis TTR, SNCA, ARSA APP 5/4885CA2 888/4885EPHX2 3145/4885
US-20050048000-A1 Amyloid targeting imaging agents and uses thereof APP, APBA1, BACE1 APP 1/4885CA2 2814/4885EPHX2 1099/4885
US-20020115717-A1 Amyloid targeting imaging agents and uses thereof APP, APBA1, BACE1 APP 1/4885CA2 2814/4885EPHX2 1099/4885
US-20140329746-A1 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES APP, PSEN1, PSEN2 APP 1/4885CA2 1085/4885EPHX2 678/4885
US-20020193395-A1 Methods and compositions to treat glycosaminoglycan-associated molecular interactions HPSE, CSGALNACT1, CD44 APP 4399/4885CA2 929/4885EPHX2 1335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.